Cargando…

A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients

PURPOSE: To characterize the population pharmacokinetics of bevacizumab, its binding properties to VEGF(165) and the effect of demographic data and VEGF-A polymorphisms on the interplay between bevacizumab serum pharmacokinetics and VEGF(165) serum concentrations in patients with colorectal cancer s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panoilia, Eirini, Schindler, Emilie, Samantas, Epaminontas, Aravantinos, Gerasimos, Kalofonos, Haralabos P., Christodoulou, Christos, Patrinos, George P., Friberg, Lena E., Sivolapenko, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365273/ https://www.ncbi.nlm.nih.gov/pubmed/25687989 http://dx.doi.org/10.1007/s00280-015-2701-3

Ejemplares similares

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
por: Papachristos, Apostolos, et al.
Publicado: (2019)

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
por: Papachristos, Apostolos, et al.
Publicado: (2020)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
por: Briasoulis, Evangelos, et al.
Publicado: (2013)

Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review
por: Papachristos, Apostolos, et al.
Publicado: (2020)

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
por: Aravantinos, Gerasimos, et al.
Publicado: (2014)

The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGF(165) and downregulating VEGF(165b)
por: Quan, Bingxuan, et al.
Publicado: (2023)

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
por: Papadimitriou, Christos A, et al.
Publicado: (2011)

VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
por: Bender, Brendan C, et al.
Publicado: (2015)

The role of VEGF-A(165)b in trophoblast survival
por: Bills, Victoria L, et al.
Publicado: (2014)

VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas
por: Corlan, Ana Silvia, et al.
Publicado: (2019)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Inhibition of retinal neovascularization by siRNA targeting VEGF(165)
por: Xia, Xiao-bo, et al.
Publicado: (2008)

Systems Pharmacology of VEGF165b in Peripheral Artery Disease
por: Clegg, Lindsay E., et al.
Publicado: (2017)

Levels of vascular endothelial growth factor-A(165b) (VEGF-A(165b)) are elevated in experimental glaucoma
por: Ergorul, Ceren, et al.
Publicado: (2008)

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014)

Heparin-Induced Changes of Vascular Endothelial Growth Factor (VEGF(165)) Structure
por: Nemashkalova, Ekaterina L., et al.
Publicado: (2023)

Effects of receptor tyrosine kinase inhibitors on VEGF(165)a- and VEGF(165)b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
por: Carter, Joanne J, et al.
Publicado: (2015)

Probing High Affinity Sequences of DNA Aptamer against VEGF(165)
por: Kaur, Harleen, et al.
Publicado: (2012)

Designing and Development of a Tandem Bivalent Nanobody against VEGF(165)
por: Khodabakhsh, Farnaz, et al.
Publicado: (2021)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Overexpression of VEGF(121), but not VEGF(165) or FGF-1, improves oxygenation in MCF-7 breast tumours
por: Fenton, B M, et al.
Publicado: (2004)

Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection
por: Lanara, Zoi, et al.
Publicado: (2013)

Development of a Multiplex Sandwich Aptamer Microarray for the Detection of VEGF(165) and Thrombin
por: Sosic, Alice, et al.
Publicado: (2013)

Angiogenic Effects of Collagen/Mesoporous Nanoparticle Composite Scaffold Delivering VEGF(165)
por: Kim, Joong-Hyun, et al.
Publicado: (2016)

Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF(165) Neutralization
por: Camacho-Villegas, Tanya A., et al.
Publicado: (2018)

The Ionophoric Activity of a Pro-Apoptotic VEGF165 Fragment on HUVEC Cells
por: Zimbone, Stefania, et al.
Publicado: (2020)

Low-potential immunosensor-based detection of the vascular growth factor 165 (VEGF(165)) using the nanocomposite platform of cobalt metal–organic framework
por: Singh, Sima, et al.
Publicado: (2020)

Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-A(165)a, VEGF-A(165)b, PIGF and VE-cadherin
por: Pang, Vincent, et al.
Publicado: (2017)

VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals
por: Yamakuchi, Munekazu, et al.
Publicado: (2023)

Secretion of VEGF-165 has unique characteristics, including shedding from the plasma membrane
por: Guzmán-Hernández, Maria Luisa, et al.
Publicado: (2014)

VEGF 165 Gene Therapy for Patients with Refractory Angina: Mobilization of Endothelial Progenitor Cells
por: Rodrigues, Clarissa G., et al.
Publicado: (2013)

Characterization and Biological Evaluation of Propolis from Poland
por: Popova, Milena, et al.
Publicado: (2017)

Pharmacokinetics of intravitreal bevacizumab (Avastin(®)) in rabbits
por: Sinapis, Christos I, et al.
Publicado: (2011)

Clinical improvement after treatment with VEGF(165) in patients with severe chronic lower limb ischaemia
por: Anghel, Andrei, et al.
Publicado: (2007)

Short and Long-Term Effects of hVEGF-A(165) in Cre-Activated Transgenic Mice
por: Leppänen, Pia, et al.
Publicado: (2006)

Ovarian VEGF(165)b expression regulates follicular development, corpus luteum function and fertility
por: Qiu, Y, et al.
Publicado: (2012)

Development and Characterization of VEGF165-Chitosan Nanoparticles for the Treatment of Radiation-Induced Skin Injury in Rats
por: Yu, Daojiang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o73mm8au90pnhibt68ma00v0bh